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Livedoid vasculopathy (LV) is a rare skin disease affec-
ting especially the calves, ankles and dorsum of the feet, 
and usually presenting with painful, purpuric macules/
papules and small ulcerations evolving into livedoid 
brownish pigmentation and stellate scars (“atrophie 
blanche”) with surrounding punctate telangiectasias; a 
history of livedo reticularis may also be present (1, 2). 
Histologically, microthromboses and segmental hyalini-
zation of the subendothelial intima of blood vessels of 
the middle/lower dermis are seen. LV is considered to 
be an occlusive vasculopathy due to a procoagulant state 
(1, 2), including protein C deficiency, factor V Leiden 
mutation, prothrombin gene mutation, increased levels 
of plasminogen activator inhibitor-1 or lipoprotein(a), 
antithrombin deficiency, and hyperhomocysteinaemia (3, 
4). Although several treatments have been used in LV, 
mainly including antiplatelet/anticoagulant agents, fibri-
nolytic/vasodilating medications and anti-inflammatory 
agent, the condition remains difficult to manage (1, 2).
We report here 2 cases of LV associated with hyper-
homocysteinaemia, which responded dramatically to 
folic acid and vitamin B6/B12 supplementation despite 
being refractory to several other therapies.
CASE REPORTS
Case 1. A 41-year-old man with numerous ex-
tremely painful stellate ulcers over a brownish 
background located on the legs and dorsal aspect 
of the feet (Fig. 1a), which had been present for 
approximately 3 months. Histological examina-
tion revealed fibrin, thrombi and necrosis of the 
dermal vessel walls, leading to a diagnosis of LV. 
Autoantibodies and routine parameters (inclu-
ding vitamins B6 and B12 levels and folic acid 
concentration) were within normal ranges. The 
patient was treated with oral steroid (methylpred-
nisolone, 0.5 mg/kg daily) and acetylsalicylic 
acid, 100 mg daily, but the lesions continued to 
worsen after 3 weeks of therapy; therefore, we 
decided to add pentoxifylline, 600 mg twice daily. However, after 
further 2 weeks we noticed only minimal amelioration of the ulcers 
and no improvement in pain. In the meantime, we received the 
results from blood tests, which showed an elevated homocysteine 
level (19.4 µmol/l) and heterozygous methylenetetrahydrofolate 
reductase (MTHFR) C677T mutation. Consequently, we decided to 
suspend the steroid and acetylsalicylic acid and start oral folic acid 
and vitamins B6/B12 supplementation (0.5 mg folic acid, 4.2 mg 
vitamin B6 and 5 µg vitamin B12 per day), with normalization of 
homocysteine level and resolution of the lesions (Fig. 1b) and pain 
after 7 weeks; there was neither clinical recurrence nor increase in 
homocysteine serum concentration after 3 months of follow-up.
Case 2. A 55-year-old woman with a 1-year history of intensely 
painful ulcerations affecting her lower extremities. Some months 
before coming to us, she was clinically diagnosed as having vascu-
litis and treated with a 2-month course of oral methylprednisolone 
(0.5 mg/kg daily), with only little improvement. When presenting 
at our clinic she was taking pentoxifylline (600 mg twice daily) for 
3 months, with minimal effects on the lesions. On physical exami-
nation, several roundish/irregular ulcerations, having a diameter 
ranging from few millimetres to 3 cm, were visible on the legs and 
dorsal aspect of the feet; moreover, some atrophic stellate scars, 
purpuric macules/papules and brownish pigmentation were also 
evident (Fig. 1c). Histology displayed dermal vessel thrombosis 
consistent with LV. Testing for hypercoagulation factors revealed 
high homocysteine level (18.2 µmol/l) associated with hetero-
zygous MTHFR C677T mutation; autoantibodies and routine 
parameters (including vitamins B6 and B12 levels and folic acid 
concentration) were within normal ranges. However, we decided 
to administer oral folic acid and vitamins B6/B12 supplementa-
tion (0.5 mg folic acid, 4.2 mg vitamin B6 and 5 µg vitamin B12 
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Fig. 1. (a) Numerous stellate ulcers over a brownish 
background located on the legs and dorsal aspect of the 
feet in Case 1; (b) resolution of the ulcerations after 7 
weeks following the introduction of vitamins B6/B12 
and folic acid supplementation. (c) Several atrophic 
stellate scars, purpuric macules/papules, brownish 
pigmentation, and roundish/irregular ulcerations on the 
legs in case 2; (d) resolution of the ulcerations after 2 
months of treatment as in (b).
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per day), which led to complete resolution of the lesions (Fig. 1d) 
and pain after 2 months, simultaneously to the normalization of 
homocysteine level. During the subsequent 2-month follow-up 
period, the patient retained the results achieved and homocysteine 
serum concentration remained within normal limits.
DISCUSSION
Homocysteine is a sulfhydryl-containing amino acid 
deriving from the demethylation of dietary methionine. 
Having high serum levels of homocysteine is considered 
to be a systemic prothrombotic condition, as this amino 
acid (and its metabolites) may be associated with endothe-
lial toxicity (3). Both inherited and non-hereditary factors 
may affect its serum concentration; including mutations 
in genes encoding enzymes involved in its metabolism 
(cystathione-β-synthase, MTHFR and methionine syn-
thase) and several acquired diseases/conditions (nutritio-
nal deficiencies, renal failure, use of folic acid and vitamin 
B6 antagonists, cardiovascular diseases and peripheral ar-
terial occlusive disease) (3, 4). The normal homocysteine 
serum level is considered to be 5–15 μmol/l (3).
Besides the well-known link between hyperhomo-
cysteinaemia and increased risk for atherosclerosis and 
venous thrombosis, there is growing evidence supporting 
the possible role of this amino acid in several skin di-
seases, including LV (3–7). In particular, Gibson et al. (6) 
observed significantly higher homocysteine concentra-
tion in subjects with LV compared with a control group 
(8.7 ± 3.1 vs. 7.0 ± 2.9 μmol/l), although the values were 
still within the normal range. More recently, serum homo-
cysteine levels exceeding the normal limit of 15 μmol/l 
have been found to correlate with LV in 2 studies, thus 
confirming a possible role of hyperhomocysteinaemia in 
the pathogenesis of this condition (3, 4). In the case repor-
ted by Meiss et al. (3), high homocysteine concentration 
was related to a combination of acquired causes, i.e. ch-
ronic renal failure/vitamins B6 and B12 deficiency, while 
in the report by Ray et al. (4) it was apparently associated 
with neither genetic factors nor acquired conditions. In-
terestingly, in the former case, lesions started to improve 
concurrent with homocysteine serum level normalization 
after 2 months of therapy with vitamins B6/B12 and folic 
acid supplementation plus heparin and pentoxifylline, 
thereby emphasizing the importance of reducing elevated 
homocysteine concentration in the healing process of LV 
(3). On the other hand, in the case reported by Ray et al. 
(4), administration of folic acid together with oral predni-
solone, pentoxyphylline and low-dose aspirin did not lead 
to any improvement after 12 weeks of treatment, but the 
lesions healed following several sessions of hyperbaric 
oxygen therapy (it was not possible to assess possible 
correlations between disease activity and homocysteine 
serum concentration in this case).
In our study, both patients with LV had hyperho-
mocysteinaemia due to a genetic factor, i.e. MTHFR 
C677T mutation. MTHFR catalyses the conversion of 
5,10-methylenetetrahydrofolate to 5-methyltetrahydro-
folate, the predominant circulatory form of folate and 
the methyl-group donor in the B12-dependent reme-
thylation of homocysteine to methionine (8, 9). C677T 
is the most common polymorphism of this enzyme 
(prevalence in the Italian population of approximately 
20% and 40% in homozygous and heterozygous state, 
respectively) (10) and gives rise to a thermolabile va-
riant of MTHFR predisposing to high homocysteine 
levels, especially in case of folate-deficient subjects (8, 
9). Treatment of patients with such a mutation is the 
same as for those presenting high homocysteine levels 
because of acquired factors, i.e. with folic acid and vi-
tamins B6/B12 supplementation (9). Its effects depend 
on the fact that homocysteine can be remethylated back 
to methionine or can be metabolized to cysteine (7–10).
Such a therapy resulted in a dramatic improvement 
in the lesions and pain in both our patients previously 
resistent to treatment, and clinical amelioration went 
hand in hand with reduction of homocysteine levels. 
These findings confirm the previously hypothesized role 
of homocystein in the pathogenesis of LV, and imply a 
necessity to investigate the homocysteine serum con-
centration (and underlying causes) in patients with this 
disease, especially if they are resistant to other therapies.
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